메뉴 건너뛰기
Journal of the Canadian Urological Association
Volumn 7, Issue 9-10 SUPPL4, 2013, Pages
How to treat the frail elderly: The challenge of multimorbidity and polypharmacy
Author keywords

[No Author keywords available]
Indexed keywords

EID: 84885913329     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.1619     Document Type: Article
Times cited : (10)
References (14)
  • 1
    • 84874422422 scopus 로고    scopus 로고
    • Frailty in elderly people
    • Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013;381:752-762. http://dx.doi.org/10.1016/S0140-6736(12)62167-9
    • (2013) Lancet , vol.381 , pp. 752-762
    • Clegg, A.1    Young, J.2    Iliffe, S.3
  • 2
    • 76049092251 scopus 로고    scopus 로고
    • Fourth International Consultation on Incontinence. Incontinence in the frail elderly: Report from the 4th International Consultation on Incontinence
    • DuBeau CE, Kuchel GA, Johnson T 2nd, et al. Fourth International Consultation on Incontinence. Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. Neurourol Urodyn 2010;29:165-78. http://dx.doi.org/10.1002/nau.20842
    • (2010) Neurourol Urodyn , vol.29 , pp. 165-178
    • Dubeau, C.E.1    Kuchel, G.A.2    Johnson II, T.3
  • 3
    • 84872322404 scopus 로고    scopus 로고
    • Comorbidities associated with bladder dysfunction
    • Tannenbaum C, Gray M, Hoffstetter S, et al. Comorbidities associated with bladder dysfunction. Int J Clin Pract 2013;67:105-13. http://dx.doi.org/10.1111/ijcp.12085
    • (2013) Int J Clin Pract , vol.67 , pp. 105-113
    • Tannenbaum, C.1    Gray, M.2    Hoffstetter, S.3
  • 4
    • 84878715750 scopus 로고    scopus 로고
    • Prevalence of commonly prescribed medications potentially contributing to urinary symptoms in a cohort of older patients seeking care for incontinence
    • Kashyap M, Tu LM, Tannenbaum C. Prevalence of commonly prescribed medications potentially contributing to urinary symptoms in a cohort of older patients seeking care for incontinence. BMC Geriatr 2013;13:57. http://dx.doi.org/10.1186/1471-2318-13-57
    • (2013) BMC Geriatr , vol.13 , pp. 57
    • Kashyap, M.1    Tu, L.M.2    Tannenbaum, C.3
  • 5
    • 84868580118 scopus 로고    scopus 로고
    • Efficacy and adverse events of antimuscarinics for treating overactive bladder: Network meta-analyses
    • Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 2012;62:1040-60. http://dx.doi.org/10.1016/j.eururo.2012.08.060
    • (2012) Eur Urol , vol.62 , pp. 1040-1060
    • Buser, N.1    Ivic, S.2    Kessler, T.M.3
  • 6
    • 79151475184 scopus 로고    scopus 로고
    • Overactive bladder drugs and constipation: A meta-analysis of randomized, placebo-controlled trials
    • Meek PD, Evang SD, Tadrous, et al. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011;56:7-18. http://dx.doi.org/10.1007/s10620-010-1313-3
    • (2011) Dig Dis Sci , vol.56 , pp. 7-18
    • Meek, P.D.1    Evang, S.D.2    Tadrous3
  • 7
    • 80051577809 scopus 로고    scopus 로고
    • Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder
    • Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011;34:733-54. http://dx.doi.org/10.2165/11592790-000000000-00000
    • (2011) Drug Saf , vol.34 , pp. 733-754
    • Oefelein, M.G.1
  • 8
    • 79960422777 scopus 로고    scopus 로고
    • Systematic review and meta-analysis: Do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?
    • Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 2011;59:1332-9. http://dx.doi.org/10.1111/j.1532-5415.2011.03473.x
    • (2011) J Am Geriatr Soc , vol.59 , pp. 1332-1339
    • Paquette, A.1    Gou, P.2    Tannenbaum, C.3
  • 9
    • 84878829234 scopus 로고    scopus 로고
    • Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: The SENIOR study
    • Wagg A, Dale M, Tretter R, et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013;64:74-81. http://dx.doi.org/10.1016/j.eururo.2013.01.002
    • (2013) Eur Urol , vol.64 , pp. 74-81
    • Wagg, A.1    Dale, M.2    Tretter, R.3
  • 10
    • 43249097485 scopus 로고    scopus 로고
    • Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence
    • Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008;56:862-70. http://dx.doi.org/10.1111/j.1532-5415.2008.01680.x
    • (2008) J Am Geriatr Soc , vol.56 , pp. 862-870
    • Lackner, T.E.1    Wyman, J.F.2    McCarthy, T.C.3
  • 11
    • 43249100527 scopus 로고    scopus 로고
    • Dual use of bladder anticholinergics and cholinesterase inhibitors: Long-term functional and cognitive outcomes
    • Sink KM, Thomas J 3rd, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008;56:847-53. http://dx.doi.org/10.1111/j.1532-5415.2008.01681.x
    • (2008) J Am Geriatr Soc , vol.56 , pp. 847-853
    • Sink, K.M.1    Thomas III, J.2    Xu, H.3
  • 12
    • 79960188172 scopus 로고    scopus 로고
    • Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction
    • Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 2011;72:186-96. http://dx.doi.org/10.1111/j.1365-2125.2010.03813.x
    • (2011) Br J Clin Pharmacol , vol.72 , pp. 186-196
    • Andersson, K.E.1    Campeau, L.2    Olshansky, B.3
  • 13
    • 77953818082 scopus 로고    scopus 로고
    • Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder
    • Andersson KE, Sarawate C, Kahler KH, et al. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2010;106:268-74. http://dx.doi.org/10.1111/j.1464-410X.2009.09073.x
    • (2010) BJU Int , vol.106 , pp. 268-274
    • Andersson, K.E.1    Sarawate, C.2    Kahler, K.H.3
  • 14
    • 84885896018 scopus 로고    scopus 로고
    • Astellas Pharma Canada, Inc. Myrbetriq™ product monograph
    • Astellas Pharma Canada, Inc. Myrbetriq™ product monograph, 2013.
    • (2013)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.